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Abstract	  	  Background	  and	  Aims	  Up	  to	  25%	  colorectal	  adenomas	  are	  missed	  during	  colonoscopy.	  Our	  aim	  was	  to	  see	  if	  the	  EndocuffTM	  vision	  could	  improve	  polyp	  detection	  in	  an	  organised	  bowel	  cancer	  screening	  programme	  (BCSP).	  	  Methods	  Parallel	  group,	  single	  blinded,	  randomised	  controlled	  trial.	  FOBT	  positive	  patients	  who	  were	  attending	  for	  BCSP	  colonoscopy	  were	  eligible	  for	  inclusion.	  The	  primary	  outcome	  was	  the	  number	  of	  polyps	  per	  patient.	  Secondary	  outcomes	  included	  the	  number	  of	  adenomas	  per	  patient,	  adenoma	  and	  polyp	  detection	  rates	  and	  withdrawal	  times.	  	  Results	  	  534	  BCSP	  patients	  were	  randomized	  to	  endocuff	  vision	  (EC)	  or	  standard	  colonoscopy	  (SC).	  The	  mean	  age	  was	  67	  years	  and	  the	  man	  to	  woman	  ratio	  was	  1.8:1.	  We	  detected	  no	  significant	  difference	  in	  the	  number	  of	  polyps	  per	  patient	  (SC	  1.77;	  EC	  1.64;	  p=0.441),	  adenomas	  per	  patient	  (SC	  1.35;	  EC	  1.26;	  p=0.536),	  polyp	  detection	  rate	  (SC	  69.8%,	  EC	  70.3%;	  p=	  0.925),	  adenoma	  detection	  rate	  (SC	  63%,	  EC	  60.9%;	  p=	  0.851),	  advanced	  adenoma	  detection	  rate	  (SC	  18.5%,	  EC	  16.9%;	  p=0.81)	  and	  cancer	  detection	  rate	  (SC	  5.7%,	  EC	  5.3%;	  p=	  0.851).	  	  	  The	  mean	  withdrawal	  time	  was	  significantly	  shorter	  among	  patients	  in	  the	  EC	  compared	  to	  SC	  group	  (16.85	  vs.	  19.47	  minutes;	  p<0.005).	  The	  endocuff	  had	  to	  be	  removed	  in	  17	  (6.4%)	  of	  patients	  because	  of	  inability	  to	  pass	  through	  the	  sigmoid	  colon.	  	  Conclusions	  This	  study	  did	  not	  find	  an	  improved	  polyp	  or	  adenoma	  detection	  with	  endocuff	  vision	   assisted	   colonoscopy	   in	   the	   FOBT	   positive	   BCSP	   population.	   A	   shorter	  withdrawal	  time	  with	  EC	  may	  reflect	   improved	  views	  and	  stability	  provided	  by	  the	  endocuff	  vision.	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Introduction	  
	  Bowel	  cancer	  is	  the	  third	  most	  common	  cancer	  in	  the	  UK	  and	  the	  second	  leading	  cause	  of	  cancer	  deaths	  [1].Colonoscopy	  and	  the	  endoscopic	  removal	  of	  adenomas	  reduce	  colorectal	  cancer	  mortality	  [2,3,4].	  For	  every	  1%	  increase	  in	  ADR	  there	  is	  a	  3%	  decrease	  in	  the	  risk	  of	  interval	  colorectal	  cancer	  [5].	  	  The	  UK	  Bowel	  cancer-­‐screening	  programme	  (BCSP)	  uses	  faecal	  occult	  blood	  test	  (FOBt)	  to	  select	  high-­‐risk	  subjects	  for	  full	  colonoscopy.	  	  	  However,	   colonoscopy	   has	   an	   inherent	   adenoma	   miss-­‐rate	   of	   up	   to	   25%[6].	  Keeping	   this	   in	  mind,	   colonoscopy	   in	   English	   BCSP	   is	   restricted	   to	   very	   select	  colonoscopists	  who	   have	   been	   carefully	   selected	   based	   on	   their	   large	   life	   time	  experience,	  excellent	  performance	  indicators	  and	  then	  accredited	  by	  undergoing	  a	  theory	  based	  exam	  and	  a	  clinical	  assessment.	  	  Modification	   of	   endoscopic	   technique,	   such	   as	   by	   increasing	  withdrawal	   times	  [7]	   have	   been	   shown	   to	   increase	   lesion	   detection.	   The	   use	   of	   smooth	   muscle	  relaxants,	   such	   as	   hyoscine	   butylbromide,	   has	   shown	   mixed	   results	   [8].	   In	  addition,	   a	   number	   of	   technologies	   and	   devices	   have	   been	   shown	   to	   improve	  polyp	  detection	  [9,10,11,12].	  However,	  none	  have	  translated	  yet	  to	  mainstream	  practice,	  as	  we	  still	  need	  well	  designed	  trials	  to	  prove	  the	  superiority	  and	  cost-­‐effectiveness	  of	  devices	  over	  the	  expertise	  of	  a	  well	  trained	  colonoscopist.	  	  The	  endocuff	  vision	  (figs.	  1-­‐3)	  is	  a	  disposable	  device	  that	  attaches	  to	  the	  end	  of	  the	  colonoscope.	  It	  has	  a	  single	  horizontal	  row	  of	  soft,	  flexible	  arms	  that	  remain	  collapsed	  during	   insertion	  but	   flare	  out	  on	  withdrawal	  to	  engage	  mucosal	   folds	  and	  flexures.	  This	  allows	  inspection	  of	  otherwise	  challenging	  areas	  and	  improves	  scope	  stability.	  It	  is	  a	  modification	  of	  the	  first-­‐generation	  endocuff,	  which	  had	  2	  rows	  of	  flexible	  arms.	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Results	   from	  randomised	  controlled	   trials	  of	   the	   first	  generation	  endocuff	  have	  demonstrated	  mixed	  success.	  Floer	  et	  al.	  demonstrated	  a	  14.7%	  increase	  in	  ADR	  compared	  to	  standard	  colonoscopy.	  	  Van	  Doorn	  et	  al	  also	  reported	  an	  increase	  in	  adenoma	  detection	  rate	  but	  no	  difference	   in	  mean	  adenomas	  per	  patient	  and	  a	  lower	   caecal	   intubation	   rate	   when	   comparing	   endocuff	   with	   standard	  colonoscopy	   [13].	   These	   studies	   did	   not	   specifically	   address	   the	   screening	  population	  and	  did	  not	  have	  strict	  standardisation	  of	  the	  endoscopist’s	  expertise.	  	  There	   are	   currently	   no	   studies	   investigating	   such	   devices	   within	   a	   screening	  population,	  where	  the	  gains	  could	  potentially	  be	  the	  greatest.	  We	  performed	  the	  first	   randomised	   controlled	   trial,	   comparing	   endocuff	   vision	   with	   standard	  practice	   in	   an	   organised	   bowel	   cancer	   screening	   programme	   where	   the	  colonoscopy	  was	  performed	  by	  accredited	  experts.	  	  Aims	  and	  objectives	  The	   aim	   of	   the	   study	   was	   to	   establish	   if	   endocuff	   vision	  assisted	   colonoscopy	  improved	  polyp	  detection	  in	  the	  Bowel	  cancer	  screening	  population.	  	  
	  
Methods	  
	  Study	  design	  This	  was	  a	  parallel	  group,	  single	  blinded,	  randomised	  controlled	  trial	  carried	  out	  at	  a	  UK	  based	  bowel	  cancer	  screening	  centre.	  Ethics	  approval	  was	  obtained	  (ref:	  14/SC/0207).	   The	   trial	   was	   adopted	   on	   to	   the	   National	   Institute	   of	   Health	  Research	   (NIHR)	   portfolio	   –	   UKCRN	   ID:	   16985.	   The	   trial	   was	   listed	   on	  clinicaltrials.gov	  -­‐	  NCT02529007.	  	  Participants	  All	   patients	   attending	   for	   Bowel	   cancer	   screening	   programme	   (BCSP)	  colonoscopy	   from	  10-­‐9-­‐2015	   to	   10-­‐9-­‐2016	  were	   included,	   provided	   they	  were	  able	   and	   willing	   to	   provide	   written	   informed	   consent.	   These	   patients	   were	  between	   59	   and	   75	   years	   of	   age	   and	   had	   a	   positive	   faecal	   occult	   blood	   test.	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Patients	  with	  a	  history	  of	   inflammatory	  bowel	  disease	  or	  polyposis	   syndromes	  were	  excluded.	  	  Colonoscopists	  All	   procedures	   were	   performed	   by	   accredited	   bowel	   cancer	   screening	  colonoscopists.	   Screening	   colonoscopists	   need	   to	   have	   a	   minimum	   lifetime	  experience	   of	   1000	   colonoscopies	   and	   fulfil	   key	   performance	   criteria	   for	  sedation	   and	   adenoma	   detection,	   before	   they	   are	   eligible	   to	   undergo	   the	  screening	  programme	  accreditation	  process.	  This	  involves	  a	  theory	  test	  and	  then	  a	  practical	  assessment	  involving	  two	  real	  time	  colonoscopy	  procedures	  assessed	  by	  two	  independent	  external	  assessors.	  	  	  Colonoscopy	  procedure	  and	  pathology	  The	   colonoscopists	   in	   the	   study	  performed	  at	   least	  15	   endocuff	   vision	  assisted	  colonoscopies	  before	  the	  commencement	  of	  the	  trial.	  Colonoscopy	  in	  both	  arms	  was	   standardised	   with	   the	   use	   of	   Olympus	   Spectrum	   CV260SL	   processor,	  Olympus	  CF-­‐H260	  endoscopes,	  CO2	  and	  Olympus	  scope	  guide.	  	  Procedures	  were	  performed	   under	   conscious	   sedation	   with	   IV	   midazolam	   and	   fentanyl.	   All	  patients	   received	   buscopan	   (hyoscine	   butylbromide)	   on	   reaching	   caecum	   and	  had	  standard	  position	  changes	  during	  withdrawal	  (cecum,	  ascending	  colon,	  and	  hepatic	   flexure:	   left	   lateral;	   transverse	   colon:	   supine;	   splenic	   flexure	   and	  descending	   colon:	   right	   lateral)	   [14].	   The	   protocol	   for	   removing	   polyps	   and	  sending	   pathology	   specimens	   did	   not	   differ	   in	   any	   way	   from	   normal	   clinical	  practice.	  Pathology	  was	  reported	  by	  specialist	  gastrointestinal	  pathologists	  in	  an	  accredited	  NHS	  hospital	   laboratory	   (Clinical	  Pathology	  Accreditation	   (CPA)	   ISO	  15189).	   The	   pathologist	   was	   blinded	   to	   the	   use	   of	   endocuff	   vision.	   An	  independent	  member	  of	   the	   research	   team	   recorded	   colonoscopy	  data	  directly	  on	  a	  case	  report	  form.	  	  	  Powering	  Data	   from	   our	   centre’s	   bowel	   cancer	   screening	   in	   previous	   years	   showed	   an	  average	   of	   1.6	   polyps	   detected	   per	   patient	   with	   a	   standard	   deviation	   of	   2.05.	  Based	  on	  previous	  studies,	  we	  postulated	  that	  endocuff	  vision	  could	  increase	  the	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polyp	  detection	  by	  30%.	  To	  detect	  an	  absolute	  difference	  between	  mean	  counts	  per	  person	  of	  0.5	  with	  80%	  power	  required	  265	  participants	  in	  each	  group,	  530	  in	  total.	  	  Informed	  consent	  and	  randomisation	  Patients	  invited	  for	  BCSP	  colonoscopy	  were	  provided	  the	  study	  information	  one	  week	   prior	   to	   their	   colonoscopy.	   On	   the	   day	   of	   the	   procedure,	   a	   good	   clinical	  practice	   (GCP)	   certified	   researcher	   met	   with	   the	   patient	   to	   obtain	   informed	  consent.	  	  	  Randomisation	  Participants	   were	   stratified	   into	   two	   groups:	   those	   attending	   for	   index	  colonoscopy	   (screening	   population)	   or	   attending	   for	   surveillance	   (surveillance	  population)	   following	   previous	   polypectomy	   within	   the	   BCSP.	   Within	   each	  population,	   participants	   were	   randomised	   to	   either	   the	   standard	   colonoscopy	  (SC)	   or	   endocuff	   vision	   assisted	   colonoscopy	   (EC)	   arm.	   Randomisation	   was	  performed	   in	   a	   1:1	   ratio	   among	   the	   two	   study	   arms	   using	   random	   permuted	  blocks	   of	   randomly	   varying	   sizes.	   The	   successive	   participants	   were	   given	   a	  sequential	  study	  number	  and	  then	  assigned	  to	  the	  associated	  intervention	  from	  the	   random	   list.	   The	   generated	   list	   was	   concealed	   in	   sequentially	   numbered	  sealed	  opaque	  envelopes,	  which	  were	  only	  opened	  to	  reveal	  the	  allocation	  after	  verifying	   that	   the	  participant	  was	  eligible	  and	  had	  consented	   to	  enter	   the	   trial.	  The	  participant	  was	  blinded	  to	  the	  allocation	  but	  not	  the	  endoscopist.	  	  	  Outcome	  measures	  and	  analysis	  The	   primary	   endpoint	   of	   the	   study	   was	   the	   mean	   polyps	   per	   patient	   (MPP),	  defined	  as	  the	  total	  number	  of	  polyps	  divided	  by	  the	  total	  number	  of	  patients	  in	  that	  group.	  	  	  The	   secondary	   endpoints	   included	   polyp	   detection	   rate	   (PDR	   –	   the	   number	   of	  procedures	   in	   which	   at	   least	   1	   polyp	   was	   detected),	   adenoma	   detection	   rate	  (ADR	  –	   the	  number	   of	   procedures	   in	  which	   at	   least	   1	   adenoma	  was	  detected),	  advanced	  adenoma	  detection	  rate	  (AADR	  –	  the	  number	  of	  adenomas	  >10mm	  in	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size),	  mean	  adenomas	  per	  patient	  (MAP	  –	  total	  number	  of	  adenomas	  divided	  by	  the	   total	   number	   of	   patients	   in	   that	   group)	   and	   cancer	   detection	   rate	   (total	  number	   of	   cancers	   divided	   by	   the	   total	   number	   of	   patients	   in	   that	   group).	  Fisher’s	  exact	  test	  was	  used	  to	  compare	  these	  outcomes.	  	  The	   caecal	   intubation	   times	   and	   total	   procedure	   times	   were	   recorded.	  Withdrawal	   times	   (time	   taken	   from	   the	   start	   of	   withdrawal	   to	   the	   end	   of	   the	  procedure)	  were	  compared	  between	  the	  two	  arms.	  A	   log	  rank	  test	  was	  used	  to	  compare	  withdrawal	  times.	  	  It	  can	  be	  challenging	  to	  get	  adequate	  views	  of	  the	  distal	  rectum	  and	  anal	  canal.	  We	  wanted	  to	  see	  if	  the	  endocuff	  vision	  could	  improve	  views	  in	  these	  challenging	  areas.	   	  Endoscopists	  were	  asked	  to	  grade	  the	  views	  of	  the	  dentate	  line	  and	  anal	  canal	  on	  direct	  withdrawal	  in	  forward	  view	  as	  excellent,	  adequate	  or	  poor	  for	  all	  the	   procedures.	   A	   Chi-­‐square	   test	   was	   used	   to	   compare	   these	   data.	   Bowel	  preparation	  for	  each	  colonoscopy	  was	  graded	  as	  per	  the	  3-­‐point	  UK	  bowel	  prep	  scoring	  system:	  Good,	  adequate	  or	  poor	  [15].	  	  Comfort	  scores	  were	  graded	  for	  all	  procedures	  as	  per	  the	  5-­‐point	  nurse	  reported	  comfort	  levels	  (NRCLs)	  used	  for	  UK	  National	  Bowel	  cancer	  screening	  colonoscopy	  procedures	  ranging	  from	  no	  discomfort	  to	  severe	  discomfort	  [16].	  The	  distribution	  of	  scores	  across	  the	  two	  arms	  was	  compared	  using	  a	  Chi-­‐square	  test.	  	  	  
Results	  534	   patients	   were	   recruited	   into	   the	   study	   between	   September	   2014	   and	  September	  2015.	  3	  patients	  were	  subsequently	  excluded	  due	  to	  the	  unexpected	  finding	   of	   hyperplastic	   polyposis	   during	   the	   colonoscopy.	   The	   remaining	   531	  were	  included	  in	  the	  final	  analysis	  (fig.4).	  	  	  The	  average	  age	  of	   the	  patients	  was	  67	  years	  and	  the	  male	  to	   female	  ratio	  was	  1.8:1.	   	   Of	   the	   patients	   that	   were	   recruited,	   371/531	   (69.9%)	   attended	   for	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screening	   (index)	   colonoscopy	   and	  160/531	   (30.1%)	   attended	   for	   surveillance	  colonoscopy	  after	  previous	  polypectomies	  under	  the	  organised	  BCSP	  (table	  1).	  	  	  265	   patients	   were	   randomised	   to	   standard	   colonoscopy	   (SC)	   and	   266	   to	  endocuff	   vision	   assisted	   colonoscopy	   (EC).	   Of	   the	  266	  patients	   recruited	   to	  EC	  arm,	   in	   17/266(6.4%)	   cases	   the	   endocuff	   vision	   had	   to	   be	   removed	  when	   the	  sigmoid	   colon	   was	   found	   to	   be	   too	   tortuous	   to	   negotiate	   with	   it	   in	   situ.	   In	  14/17(82.3%)	  cases,	  this	  resolved	  the	  problem	  and	  the	  colonoscopy	  could	  then	  be	  completed.	  	  Polyp,	  adenoma	  and	  cancer	  detection	  
Whole	  population	  On	   intention	   to	   treat	  analysis,	  470	  polyps	   (MPP	  –	  1.7)	  were	  detected	   in	   the	  SC	  group	  as	  compared	  to	  436	  polyps	  (MPP	  –	  1.6)	   in	   the	  EC	  group	  (table	  2).	  There	  was	  no	  significant	  difference	  between	  the	  2	  groups	  (p=0.441)	  	  	  359	   adenomas	   (MAP	   –	   1.3)	   were	   detected	   in	   the	   SC	   group	   vs.	   336	   adenomas	  (MAP	  –	  1.2)	  in	  the	  EC	  group	  (p=0.536).	  The	  adenomas	  accounted	  for	  76%	  of	  all	  our	  polyps.	  	  	  No	  significant	  difference	  was	  found	  between	  the	  two	  groups	   in	  polyp	  detection	  rate	   (SC-­‐	   69.8%,	   EC-­‐	   70.3%;	   p=	   0.925),	   adenoma	   detection	   rate	   (SC-­‐	   63%,	   EC-­‐	  60.9%;	   p=	   0.851),	   advanced	   adenoma	   detection	   rate	   (SC-­‐	   18.5%,	   EC-­‐	   16.9%;	  p=0.81)	  and	  cancer	  detection	  rate	  (SC-­‐	  5.7%,	  EC-­‐	  5.3%;	  p=	  0.851).	  	  	  
Screening	  and	  surveillance	  populations	  –	  sub-­‐analysis	  A	   sub-­‐analysis	   was	   performed	   in	   the	   screening	   and	   surveillance	   populations	  separately.	   As	   expected,	   smaller	   numbers	   of	   polyps	   were	   detected	   in	   the	  surveillance	  population	   (266	  polyps)	   as	   compared	   to	   the	   screening	  population	  (640	  polyps).	  However,	  no	  significant	  difference	  was	  seen	  between	  the	  two	  study	  arms	  for	  any	  of	  these	  outcomes	  in	  either	  the	  screening	  group	  or	  the	  surveillance	  group.	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Polyp	  size	  based	  analysis	  A	  polyp	  size	  based	  analysis	  was	  performed	  to	  see	  if	  there	  was	  a	  difference	  in	  the	  size	  of	  polyps	  detected	  in	  the	  2	  groups	  (fig.5).	  A	  Chi	  square	  test	  indicated	  that	  significantly	  more	  medium	  sized	  (6-­‐10mm)	  polyps	  were	  detected	  in	  the	  SC	  arm	  as	  compared	  to	  the	  EC	  arm	  (SC-­‐76,	  EC-­‐46;	  p=0.020).	  There	  was	  no	  significant	  difference	  between	  the	  2	  arms	  in	  the	  detection	  of	  diminutive	  (<5mm)	  and	  large	  (>10mm)	  sized	  polyps.	  	  Endoscopist	  based	  analysis	  The	  data	  for	  each	  colonoscopist	  were	  evaluated	  separately	  to	  look	  for	  any	  significant	  differences	  in	  lesion	  detection	  rates	  between	  the	  four	  different	  colonoscopists	  in	  the	  study.	  When	  analysing	  for	  one	  endoscopist	  at	  a	  time,	  no	  significant	  difference	  was	  found	  in	  these	  outcomes	  between	  SC	  and	  EC	  (table	  3).	  	  
	  Effect	  of	  trial	  on	  the	  performance	  of	  the	  endoscopists	  (study	  bias)	  We	  looked	  at	  the	  ADRs	  of	  the	  study	  endoscopists	  in	  the	  6	  months	  prior	  to	  the	  start	  of	  the	  study	  and	  compared	  these	  to	  their	  ADRs	  in	  the	  SC	  arm	  during	  the	  study.	  	  Their	  pre-­‐study	  ADR	  averaged	  58.9%	  and	  did	  not	  change	  significantly	  during	  the	  study.	  	  Withdrawal	  and	  intubation	  times	  The	  mean	  withdrawal	  time	  for	  all	  cases	  in	  the	  study	  was	  18.16	  minutes.	  The	  mean	  withdrawal	  time	  was	  19.47	  minutes	  in	  the	  SC	  arm,	  which	  was	  significantly	  longer	  from	  the	  mean	  withdrawal	  time	  of	  16.85	  minutes	  in	  the	  EC	  arm	  (p<0.005)	  (table	  1)	  	  There	  was	  no	  significant	  difference	  in	  the	  intubation	  times	  between	  the	  2	  groups	  (15.75	  minutes	  for	  EC	  vs.	  15.89	  minutes	  for	  SC;	  p=0.86).	  	  The	  mean	  total	  procedure	  time	  was	  shorter	  in	  the	  EC	  group	  (32.8	  minutes)	  as	  compared	  to	  the	  SC	  group	  (35.28	  minutes).	  However,	  this	  difference	  was	  not	  statistically	  significant	  (p=0.11).	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  Views	  of	  the	  dentate	  line	  and	  anal	  canal	  Views	  were	  graded	  as	  excellent	  in	  67.6%	  patients	  in	  the	  EC	  group	  and	  61.9%	  in	  the	  SC	  group.	  However,	  this	  failed	  to	  achieve	  significance.	  All	  endoscopists	  graded	  the	  views	  as	  excellent	  more	  frequently	  for	  the	  EC	  group.	  However,	  the	  difference	  from	  the	  SC	  group	  was	  not	  significant	  (p=0.05).	  	  Comfort	  scores	  Comfort	  scores	  were	  graded	  for	  all	  procedures	  on	  a	  5-­‐point	  scale	  with	  no	  discomfort	  being	  scored	  as	  0	  and	  severe	  discomfort	  scored	  as	  4.	  A	  Chi-­‐square	  test	  of	  homogeneity	  demonstrated	  no	  significant	  difference	  in	  comfort	  scores	  between	  the	  SC	  and	  EC	  arms	  (p=0.268)	  with	  a	  mean	  comfort	  score	  of	  1.57	  in	  the	  EC	  group	  and	  1.46	  in	  the	  SC	  group.	  	  Complications	  No	  significant	  complications	  were	  seen	  in	  either	  study	  arm.	  There	  was	  1	  post	  polypectomy	  bleed	  in	  the	  SC	  arm,	  which	  was	  identified	  immediately	  and	  controlled	  with	  the	  application	  of	  clips.	  	  
Discussion	  This	  is	  the	  first	  randomised	  controlled	  trial	  evaluating	  any	  generation	  endocuff	  in	  an	  organised	  National	  bowel	  cancer	  screening	  population.	  	  	  	  	  	  The	  endocuff	  vision	  did	  not	  increase	  polyp	  or	  adenoma	  yield	  in	  the	  hands	  of	  highly	  experienced	  colonoscopists	  in	  this	  FOBT	  positive	  screening	  population.	  The	  overall	  mean	  polyps	  per	  patient,	  mean	  adenomas	  per	  patient,	  polyp	  detection	  rate	  &	  adenoma	  detection	  rate	  were	  similar	  in	  the	  control	  and	  EC	  arms.	  Our	  study	  demonstrated	  that	  it	  was	  possible	  to	  achieve	  caecal	  intubation	  in	  93.6%	  of	  patients	  without	  removing	  the	  endocuff	  vision.	  There	  were	  no	  safety	  concerns	  and	  it	  did	  not	  increase	  patient	  discomfort.	  	  	  However,	  the	  mean	  withdrawal	  time	  was	  significantly	  shorter	  in	  the	  EC	  arm	  (16.85	  minutes	  vs.	  19.47	  minutes;	  p<0.005).	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  The	  most	  significant	  finding	  from	  this	  study	  is	  the	  lack	  of	  an	  improvement	  in	  polyp	  or	  adenoma	  detection	  with	  the	  use	  of	  the	  endocuff	  vision.	  	  Our	  data	  demonstrates	  that	  if	  endoscopists	  have	  a	  very	  high	  PDR	  and	  ADR	  in	  a	  BCSP,	  then	  devices	  like	  the	  endocuff	  are	  unlikely	  to	  be	  of	  benefit.	  	  To	  date,	  three	  large	  randomised	  controlled	  trials	  comparing	  the	  first	  generation	  endocuff	  with	  standard	  colonoscopy	  have	  been	  published.	  A	  large	  study	  from	  the	  Netherlands	  with	  over	  1,000	  participants	  suggested	  a	  trend	  towards	  improved	  adenoma	  detection,	  although	  this	  was	  not	  statistically	  significant	  and	  there	  was	  no	  significant	  increase	  in	  the	  number	  of	  adenomas	  per	  patient	  with	  EC	  [16].	  Our	  study	  did	  not	  suggest	  any	  trend	  towards	  significance	  although	  it	  should	  be	  noted	  that	  our	  patient	  population	  was	  quite	  different,	  being	  entirely	  FOB	  positive.	  It	  is	  important	  to	  note	  that	  the	  authors	  in	  the	  above	  study	  performed	  a	  sub-­‐analysis	  of	  FIT	  positive	  patients	  and	  noted	  no	  significant	  difference	  in	  adenoma	  detection	  (P=0.52).	  This	  would	  be	  in	  keeping	  with	  our	  findings,	  and	  reflects	  the	  importance	  of	  examining	  a	  device	  within	  a	  specific	  patient	  population.	  	  	  There	  are	  a	  few	  studies	  however,	  that	  have	  reported	  an	  improvement	  in	  polyp/adenoma	  detection	  with	  the	  endocuff.	  In	  a	  randomised	  study	  from	  Germany	  with	  498	  patients,	  the	  MPP	  was	  significantly	  better	  with	  EC	  than	  with	  SC	  (2.00	  vs.	  1.00;	  p<0.0001)	  [18].	  Another	  study	  from	  the	  same	  group	  showed	  a	  significantly	  improved	  ADR	  with	  EC	  (35.4%	  vs.	  20.9%;	  p<0.0001)[19].	  Compared	  to	  our	  study,	  the	  ADRs	  in	  this	  study	  were	  much	  lower,	  particularly	  in	  the	  SC	  arm.	  Another	  recent	  study	  has	  also	  shown	  improved	  ADRs	  with	  EC	  ((29.6%	  vs.	  26.3%,	  p<0.01),	  though	  the	  ADRs	  were	  again	  very	  low	  [20].	  The	  consistent	  observation	  from	  these	  studies	  is	  a	  low	  polyp	  /	  adenoma	  detection	  in	  the	  control	  arm	  and	  the	  reason	  behind	  this	  is	  not	  clear.	  This	  could	  potentially	  be	  related	  to	  either	  the	  endoscopists	  or	  population	  included	  in	  these	  studies.	  The	  other	  observation	  of	  note	  here	  is	  that	  the	  MPP	  and	  ADR	  in	  the	  control	  arm	  of	  the	  study	  from	  the	  Amsterdam	  group	  and	  our	  current	  study	  are	  very	  high	  and	  in	  both	  these	  studies	  the	  endocuff	  has	  shown	  no	  improvement	  in	  MPP	  or	  ADR.	  Given	  the	  above	  observations,	  it	  is	  not	  unreasonable	  to	  speculate	  that	  the	  observed	  benefits	  of	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endocuff	  in	  some	  of	  the	  studies	  could	  be	  a	  reflection	  of	  poor	  polyp	  detection	  in	  the	  control	  arms,	  as	  the	  reported	  polyp	  and	  adenoma	  rates	  in	  the	  control	  arms	  of	  these	  studies	  is	  lower	  then	  expected.	  We	  believe	  that	  future	  studies	  with	  similar	  devices	  should	  keep	  these	  factors	  into	  consideration.	  	  	  We	  have	  reported	  significantly	  shorter	  withdrawal	  times	  (15%	  reduction)	  in	  the	  EC	  arm	  as	  compared	  to	  the	  SC	  arm.	  This	  could	  be	  due	  to	  improved	  views	  and	  stability	  provided	  by	  the	  endocuff	  vision	  during	  withdrawal.	  This	  is	  really	  important,	  as	  the	  endoscopists	  in	  the	  EC	  arm	  have	  detected	  the	  same	  number	  of	  polyps	  and	  adenomas	  as	  in	  the	  standard	  arm	  but	  in	  a	  much	  shorter	  time.	  The	  small	  additional	  cost	  of	  endocuff	  vision	  could	  potentially	  be	  neutralized	  by	  the	  reduction	  in	  withdrawal	  and	  overall	  procedure	  times;	  thereby	  making	  colonoscopy	  more	  time	  efficient.	  Similar	  findings	  were	  observed	  by	  the	  Netherlands	  group	  and	  we	  suspect	  that	  this	  is	  not	  artefactual.	  However,	  this	  needs	  to	  be	  formally	  evaluated.	  There	  was	  a	  trend	  towards	  significance	  in	  the	  endoscopists’	  grading	  of	  mucosal	  views	  in	  the	  area	  around	  the	  dentate	  line,	  with	  views	  being	  graded	  as	  excellent	  in	  67.6%	  patients	  in	  the	  EC	  group	  and	  61.9%	  in	  the	  SC	  group	  (p=0.05).	  	  A	  surprising	  finding	  from	  our	  study	  was	  a	  reduction	  in	  the	  number	  of	  medium	  sized	  (5-­‐10mm)	  polyps	  with	  endocuff	  vision	  compared	  to	  the	  standard	  limb	  (P=0.020).	  This	  could	  reflect	  the	  change	  in	  technique	  required	  to	  withdraw	  using	  the	  endocuff	  vision.	  Traditional	  colonoscopy	  requires	  repeated	  reinsertion	  and	  withdrawal	  to	  visualise	  all	  of	  the	  folds	  with	  maximal	  distension.	  To	  use	  endocuff	  vision	  effectively	  requires	  over	  distension	  to	  be	  avoided	  to	  enable	  the	  flanges	  to	  engage	  with	  the	  folds,	  and	  less	  slippage	  will	  make	  the	  endoscopist	  feel	  less	  inclined	  to	  reinsert	  and	  re-­‐examine	  areas.	  These	  findings	  should	  be	  interpreted	  with	  caution,	  as	  the	  study	  was	  not	  powered	  to	  investigate	  this.	  The	  most	  likely	  explanation	  is	  that	  it	  is	  a	  statistical	  artefact,	  but	  it	  could	  be	  a	  focus	  for	  further	  investigation.	  	  	  The	  endocuff	  vision	  did	  not	  come	  off	  in	  any	  case	  and	  was	  a	  good	  fit	  for	  the	  scope.	  Difficult	  sigmoid	  colons	  with	  complex	  diverticulosis	  are	  always	  challenging.	  
	   14	  
Since	  our	  study	  population	  was	  between	  59	  and	  75	  years	  of	  age,	  the	  prevalence	  of	  diverticulosis	  was	  high.	  Despite	  this	  the	  endocuff	  vision	  had	  to	  be	  removed	  in	  only	  6%	  of	  patients	  in	  order	  to	  negotiate	  a	  tortuous	  sigmoid.	  	  	  The	  study	  has	  a	  number	  of	  strengths.	  It	  is	  the	  first	  study	  to	  investigate	  endocuff	  vision	  in	  an	  organised	  FOBT	  based	  National	  bowel	  cancer	  screening	  population.	  It	  is	  large	  and	  well	  powered.	  The	  endoscopists,	  colonoscopy	  technique	  and	  the	  study	  population	  are	  all	  very	  well	  standardised	  and	  controlled.	  	  We	  have	  also	  controlled	  for	  a	  study	  related	  in-­‐trial	  bias	  by	  comparing	  the	  pre	  study	  ADR	  of	  our	  endoscopists	  to	  the	  ADR	  during	  the	  study.	  Our	  endoscopists	  were	  experts	  and	  very	  high	  performing	  with	  a	  baseline	  ADR	  of	  58.9%	  in	  the	  FOBT	  positive	  screening	  population	  before	  the	  start	  of	  the	  study.	  	  A	  potential	  criticism	  of	  our	  study	  is	  that	  the	  primary	  end	  point	  was	  polyp	  rather	  than	  adenoma	  detection	  rates.	  However,	  there	  is	  growing	  data	  to	  support	  the	  importance	  of	  right-­‐sided	  serrated	  polyps	  in	  the	  development	  of	  cancer.	  Given	  that	  there	  is	  a	  need	  within	  bowel	  cancer	  screening	  to	  reduce	  right-­‐sided	  bowel	  cancer	  risk	  it	  is	  our	  contention	  that	  ADR	  is	  not	  an	  adequate	  measure	  in	  this	  patient	  population	  and	  by	  looking	  at	  all	  polyps	  we	  have	  taken	  this	  into	  account.	  Furthermore,	  endocuff	  vision	  is	  a	  device	  designed	  to	  find	  polyps,	  not	  to	  differentiate	  histology.	  It	  is	  therefore	  inappropriate	  to	  attempt	  to	  look	  simply	  for	  adenomas,	  as	  it	  is	  not	  an	  appropriate	  measure	  of	  the	  effectiveness	  of	  the	  device.	  In	  this	  study,	  the	  endoscopists	  could	  not	  be	  blinded	  to	  the	  randomisation.	  However,	  the	  ADR	  (63%	  for	  SC	  vs.	  60.95%	  for	  EC)	  and	  the	  number	  of	  adenomas	  per	  patient	  (1.35	  for	  SC	  vs.	  1.26	  for	  EC)	  were	  closely	  comparable.	  These	  are	  the	  most	  important	  surrogate	  markers	  of	  the	  quality	  of	  colonoscopy.	  Comparable	  values	  in	  the	  2	  arms	  therefore	  make	  selection/observer	  bias	  unlikely.	  In	  addition,	  the	  in-­‐trial	  ADRs	  of	  the	  endoscopists	  compared	  very	  closely	  with	  the	  pre-­‐trial	  ADRs,	  thus	  further	  ruling	  out	  in-­‐trial	  observer	  bias.	  	  
Conclusion	  This	  is	  the	  first	  randomised	  controlled	  study	  of	  the	  endocuff	  vision	  in	  an	  organised	  FOBT	  based	  national	  bowel	  cancer	  screening	  population	  and	  showed	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no	  significant	  difference	  in	  polyp	  or	  adenoma	  detection	  between	  standard	  and	  endocuff	  vision	  assisted	  colonoscopy..	  The	  withdrawal	  times	  were	  significantly	  faster	  in	  the	  EC	  arm	  and	  could	  be	  due	  to	  improved	  views	  and	  stability	  provided	  by	  the	  endocuff	  vision.	  No	  significant	  adverse	  events	  were	  seen.	  We	  conclude	  that	  whilst	  endocuff	  vision	  is	  safe	  and	  reduces	  withdrawal	  time,	  it	  does	  not	  improve	  polyp	  detection	  during	  FOBT	  positive	  screening	  colonoscopy	  in	  an	  organised	  screening	  programme.	  	   	  
	   16	  
	   SC	  (n=265)	   EC	  (n=266)	  
Median	  age	  (yrs.)	   67	  (IQR	  64-­‐71)	   68	  (IQR	  63-­‐70)	  
Males–	  n	  (%)	   180	  (68%)	   162	  (61%)	  
Indications	   	   	  
	  	  	  	  Positive	  FoBT–	  n	  (%)	   183(69%)	   188	  (70%)	  
	  	  	  	  Polyp	  surveillance	  –	  	  
n	  (%)	  
82	  (31%)	   78	  (29%)	  
Good/adequate	  bowel	  
prep	  –	  n	  (%)	  
259	  (98%)	   260	  (98%)	  
Withdrawal	  time	  (all	  
cases)	  in	  minutes	  –	  
mean±SD	  
19.5±12.2	   16.8±8.3	  
Table1.	  	  Patient	  characteristics	  and	  withdrawal	  time.	  IQR,	  Interquartile	  range;	  FoBT,	  Faecal	  occult	  blood	  test	  	  
	   SC	  (n=265)	   EC	  (n=266)	   	  
Polyps	  -­‐	  n	   470	   436	   	  
MPP	  -­‐	  mean±	  SD	   1.7±2.0	   1.6±1.9	   p=	  0.44	  
Adenomas	  -­‐	  n	   359	   336	   	  
MAP	  -­‐	  mean±	  SD	   1.3±1.5	   1.2±1.8	   p=	  0.53	  
PDR	   69.8%	   70.3%	   p=	  0.92	  
ADR	   63%	   60.9%	   p=	  0.85	  
Proximal	  polyps-­‐	  
n(%)	  
169	  (36%)	   148	  (34%)	   p=0.52	  
Proximal	  adenomas-­‐	  
n(%)	  
140(39%)	   128	  (38%)	   p=0.81	  
Advanced	  ADR	   18.5%	   16.9%	   p=0.81	  
Cancer	  detection	  
rate	  
5.7%	   5.3%	   	  p=	  0.85	  
Table	  2.	  Polyp,	  adenoma	  and	  cancer	  detection.	  MPP,	  Mean	  polyps	  per	  patient;	  MAP,	  Mean	  adenomas	  per	  patient;	  PDR,	  Polyp	  detection	  rate;	  ADR,	  Adenoma	  detection	  rate;	  Advanced	  ADR,	  proportion	  of	  cases	  in	  which	  at	  least	  one	  adenoma	  >10mm	  in	  size	  was	  detected;	  Proximal,	  proximal	  to	  splenic	  flexure.	  	  
	   Endoscopist	  1	   Endoscopist	  2	   Endoscopist	  3	   Endoscopist	  4	  
	   SC	   EC	   SC	   EC	   SC	   EC	   SC	   EC	  No.	  	  Participants	   122	   108	   90	   107	   30	   25	   23	   26	  Polyps	  -­‐	  n	   234	   194	   138	   138	   48	   52	   50	   52	  MPP-­‐	  mean±SD	   1.9±2.2	   1.8±2.2	   1.5±1.4	   1.3±1.5	   1.6±1.7	   2.1±1.5	   2.2±3.4	   2.0±2.1	  P	  =	  0.66	   P	  =	  0.11	   P	  =	  0.11	   P	  =	  0.53	  Adenomas	  -­‐	  n	   183	   156	   107	   110	   37	   36	   32	   34	  MAP-­‐	  mean±SD	   1.5±1.7	   1.4±2.2	   1.2±1.2	   1.0±1.4	   1.2±1.5	   1.4±1.3	   1.4±2.0	   1.3±1.6	  P	  =	  0.52	   P	  =	  0.06	   P	  =	  0.32	   P	  =	  0.88	  PDR	   66.4%	  	   72.2%	  	   75.6%	   63.5%	  	   73.3%	   88.0%	   	  60.9%	   	  73.1%	  P=0.34	   P=0.06	   P=0.17	   P=0.36	  ADR	   57.4%	  	   62.0%	  	   67.8%	   51.4%	   60.0%	   72.0%	   	  56.5%	   	  57.7%	  P=0.47	   P=0.05	   P=0.35	   P=0.93	  Cancer	  detection	  rate	   4.9%	  	   2.8%	  	   6.7%	   5.6%	   	  3.3%	   	  4.0%	   	  8.7%	   	  15.4%	  P=0.40	   P=0.75	   P=0.89	   P=0.47	  
Table	  3.	  Results	  by	  endoscopist.	  MPP,	  Mean	  polyps	  per	  patient;	  MAP,	  Mean	  adenomas	  per	  patient;	  PDR,	  Polyp	  detection	  rate;	  ADR,	  Adenoma	  detection	  rate	  PDR,	  Polyp	  detection	  rate;	  ADR,	  Adenoma	  detection	  rate.	  	  	  
	   17	  
	   18	  
	   19	  
	  	  	   	  
	   20	  
	  	  	  Fig.	  4	  –	  CONSORT	  flow	  diagram	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  Fig.	  5.	  Polyp	  size	  based	  analysis.	  6-­‐10mm	  polyps:	  SC	  –	  76,	  EC	  –	  46;	  p=0.02	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  Figures	  legend	  Figs.1,	  2	  and	  3–	  Endocuff	  vision	  Fig.	  4	  –	  CONSORT	  flow	  diagram	  Fig.	  5.	  Polyp	  size	  based	  analysis.	  6-­‐10mm	  polyps:	  SC	  –	  76,	  EC	  –	  46;	  p=0.02	  	  	  	  	  	  
